Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CENTER FOR PAIN MANAGEMENT, LLC

NPI: 1689004277 · COLUMBIA, MD 21045 · Interventional Pain Medicine Physician · NPI assigned 11/18/2013

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official TINCH, SHANEKA controls 16+ related entities in our dataset. Read more

$15K
Total Medicaid Paid
4,254
Total Claims
3,651
Beneficiaries
4
Codes Billed
2018-01
First Month
2019-11
Last Month

Provider Details

Authorized OfficialTINCH, SHANEKA (RCM MANAGER)
NPI Enumeration Date11/18/2013

Related Entities

Other providers sharing the same authorized official: TINCH, SHANEKA

ProviderCityStateTotal Paid
CENTER FOR PAIN MANAGEMENT, LLC HAGERSTOWN MD $18.80M
INTERVENTIONAL PAIN CENTER PLLC FAYETTEVILLE NC $6.14M
PHYSICAL MEDICINE ASSOCIATES, LTD MC LEAN VA $1.79M
ASC DEVELOPMENT COMPANY, LLC HAGERSTOWN MD $113K
ASC DEVELOPMENT COMPANY, LLC FREDERICK MD $42K
ASC DEVELOPMENT COMPANY, LLC GERMANTOWN MD $31K
FLORIDA PAIN AND REHABILITATION ASSOCIATES INC DELRAY BEACH FL $25K
ASC DEVELOPMENT COMPANY, LLC PIKESVILLE MD $24K
ASC DEVELOPMENT COMPANY, LLC GLEN BURNIE MD $24K
ASC DEVELOPMENT COMPANY LLC WHITE PLAINS MD $14K
ASC DEVELOPMENT COMPANY, LLC BEL AIR MD $7K
NSPC SURGERY CENTER OF MARYLAND LLC OXON HILL MD $6K
NATIONAL SURGICAL CENTERS OF AMERICA LLC WINTER PARK FL $2K
FLORIDA PAIN AND REHABILITATION ASSOCIATES INC DELRAY BEACH FL $377.09
PAIN CONSULTANTS ASC LLC PASCAGOULA MS $0.00
PHYSICAL MEDICINE ASSOCIATES LTD OXON HILL MD $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,443 $10K
2019 1,811 $5K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,249 1,923 $6K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 904 761 $5K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 960 832 $2K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 141 135 $2K